#274 – Performance-enhancing drugs and hormones: risks, rewards, and broader implications for the public | Derek: More Plates, More Dates
“There’s no drug that’s purely selective exactly where you want and it’s perfect.” —Derek – More Plates More Dates
#273 ‒ Prostate health: common problems, cancer prevention, screening, treatment, and more | Ted Schaeffer, M.D., Ph.D.
“The faster that your PSA density rises, it is a canary in the coal mine. . .you need to do some additional evaluation.” —Ted Schaeffer
#272 ‒ Rapamycin: potential longevity benefits, surge in popularity, unanswered questions, and more | David Sabatini, M.D., Ph.D. and Matt Kaeberlein, Ph.D.
“[Rapamycin] is the most robust and reproducible drug that we know about today for impacting not only longevity, but to the extent that we can measure various metrics of healthspan in complex animals, rapamycin also seems to positively impact pretty much every aspect of health span that we measure.” —Matt Kaeberlein
#268 ‒ Genetics: testing, therapy, editing, association with disease risk, autism, and more | Wendy Chung, M.D., Ph.D.
“There are literally tens of thousands of genetic variants in your genome, and what they mean and whether or not they do anything whatsoever is hard to know.” —Wendy Chung
#266 – AMA #50: Genetics: how they impact disease risk, what you can do about it, testing, and more
“With how much uncertainty there is in genetic testing, I just think everybody needs to be thoughtful about it before they do it.” —Peter Attia
#265 – Time, productivity, and purpose: insights from Four Thousand Weeks | Oliver Burkeman
“Part of living a meaningful life is to be conscious of that fact that we don’t get all the time we would wish to have.” —Oliver Burkeman